对早老性阿尔茨海默病患者进行GM1神经节苷脂的肠胃外给药。

Parenteral administration of GM1 ganglioside to presenile Alzheimer patients.

作者信息

Svennerholm L, Gottfries C G, Blennow K, Fredman P, Karlsson I, Månsson J E, Toffano G, Wallin A

机构信息

Department of Psychiatry and Neurochemistry, Gothenburg University, Sweden.

出版信息

Acta Neurol Scand. 1990 Jan;81(1):48-53. doi: 10.1111/j.1600-0404.1990.tb00930.x.

DOI:10.1111/j.1600-0404.1990.tb00930.x

PMID:2330815

Abstract

The pharmacokinetic parameters of GM1 ganglioside were examined in 16 patients (mean age 64 +/- 5 years) with Alzheimer's disease. The ganglioside was given intramuscularly and subcutaneously. The maximum GM1 blood level was reached after 48-72 h, the subcutaneous route leading to the highest blood levels, but the individual variability was relatively large. When 100 mg GM1 ganglioside was given daily for a week, maximum serum values of 15 to 20 mumol/l were found in 3 patients. The elimination half-life from serum was 60-75 h.

摘要

对16例（平均年龄64±5岁）阿尔茨海默病患者进行了GM1神经节苷脂的药代动力学参数研究。该神经节苷脂通过肌肉注射和皮下注射给药。48 - 72小时后达到GM1血药浓度峰值，皮下给药途径导致血药浓度最高，但个体差异相对较大。当每天给予100mg GM1神经节苷脂，持续一周时，3例患者的血清最大值为15至20μmol/L。血清消除半衰期为60 - 75小时。